Eli Lilly & Co.

Study shows Cymbalta reduces depression symptoms at least as fast as Lexapro

Published in Pharma Law Weekly, January 10th, 2006

Cymbalta (duloxetine hydrochloride) reduced symptoms of depression at least as fast as Lexapro (escitalopram) by the end of 2 weeks, according to results from the first head-to-head study comparing the two antidepressants.

The results were released by Eli Lilly and Company at a meeting of a major scientific society.

In this 8-week study, Cymbalta, a serotonin and norepinephrine reuptake inhibitor, was effective in reducing depression symptoms (defined as onset of efficacy) by 2 weeks for 42% of patients. Within the same time period, 35% of patients taking Lexapro, a selective serotonin reuptake inhibitor, and 22% of patients who received a sugar pill...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Pharma Law Weekly

Source: Pharma Law Weekly (2006-01-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry